Actively Recruiting
Role of Coagulation, Inflammation and Vessels in Chronic Liver Disease
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2024-08-01
360
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic liver diseases cause significant health problems and over 150,000 deaths annually in Europe. These conditions affect working-age individuals and greatly impact quality of life and the economy. Researchers are investigating the roles of blood clotting problems, inflammation, and blood vessel changes in the development and worsening of these diseases to improve patient care and outcomes. Participants include people with chronic liver disease at various stages, from no cirrhosis to advanced liver failure, as well as control participants without liver disease. The study collects blood samples from all participants on the day they join to analyze factors related to blood clotting and disease progression. This observational study aims to better understand how coagulation contributes to chronic liver disease and its complications. During the study, participants undergo blood draws at inclusion to measure multiple blood clotting factors and related markers over a period of up to 10 years. Researchers will assess abnormalities in these factors in patients at different disease stages and compare them to controls. The long-term monitoring will help clarify the role of coagulation in disease development and support improved management strategies.
CONDITIONS
Brief Title
Role of Coagulation, Inflammation and Vessels in Chronic Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years of age
- Patients affiliated with a social security plan or entitled to receive benefits
- Patients with chronic liver disease or cirrhosis diagnosed by liver biopsy, liver elastography >10 kPa, or clinical, biological, and imaging criteria
- Control patients 18 years or older without known liver disease who have had blood drawn prior to surgery
You will not qualify if you...
- Pregnant or lactating women
- Persons under guardianship, curatorship, or safeguard of justice
- Patients under AME
- Patients who have not signed a consent form
- Recent surgery within 2 weeks before blood test
- Recent blood transfusion within 2 weeks
- Use of medication interfering with hemostasis
- Active extra-hepatic cancer or cancer within the last 5 years
- History of organ transplantation (liver, kidney, lung, heart)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants provide a blood sample on the day of inclusion to assess coagulation factors and other biomarkers related to chronic liver disease.
1 visit (in-person)
Duration - Up to 10 years
Participants are observed over time to study the progression of coagulation abnormalities and liver disease complications.
Follow-up visits as scheduled by the study team
Trial Site Locations
Total: 1 location
1
Beaujon Hospital
Clichy, France
Actively Recruiting
Research Team
P
Pierre Emmanuel Rautou
A
Alix Riescher-Tuczkiewicz
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here